BACKGROUND: The warm-up phenomenon observed after the second of two sequential exercise tests is characterized by an increased time to ischemia and ischemic threshold, and the latter is related to ischemic preconditioning. Previous studies have demonstrated that a single dose of glibenclamide, a cardiac ATP-sensitive K (K(ATP)) channel blocker, prevents ischemic preconditioning. This study aimed to investigate the effects of chronic treatment with glibenclamide during two sequential exercise tests. METHODS:Forty patients with angina pectoris were divided into three groups: 20 nondiabetics (NDM), 10 patients with diabetes in treatment withglibenclamide (DMG) and 10 diabetic patients with other treatments (DMO). All patients underwent two consecutive exercise tests. RESULTS:Heart rate and rate-pressure product at 1.0 mm ST-segment depression significantly increased during the second exercise test in NDM group (121.3+/-16.5 vs 127.3+/-15.3 beats/min, P<0.001, and 216.7+43.1 vs 232.1+/-43.0 beats.min-1.mmHg.10(2), P<0.001), and in DMO group (114.1+/-19.6 vs 119.6+/-18.1 beats/min, P=0.001, and 199.8+/-36.6 vs 222.2+/-29.2 beats.min-1.mmHg.10(2), P=0.019), but it did not change in patients in DMG group (130.7+/-14.5 vs 132.1+/-4.7 beats/min, P=ns, and 251.7+/-47.2 vs 250.3+/-42.8 beats.min-1.mmHg.10(2), P=ns). In the three groups, NDM, DMO, and DMG, the time to 1.0 mm ST-segment depression during the second exercise test was greater than during the first (225.0+/-112.5 vs 267.0+/-122.3 seconds, P=0.006; 187.5+/-54.0 vs 226.5+/-74.6 seconds, P=0.029 and 150.0+/-78.7 vs 186.0+/-81.9 seconds, P<0.001). CONCLUSION: The chronic use of glibenclamide may have mediated the loss of preconditioning benefits in the warm-up phenomenon, probably through its KATP channel-blocker activity, but without acting upon the tolerance to exercise.
RCT Entities:
BACKGROUND: The warm-up phenomenon observed after the second of two sequential exercise tests is characterized by an increased time to ischemia and ischemic threshold, and the latter is related to ischemic preconditioning. Previous studies have demonstrated that a single dose of glibenclamide, a cardiac ATP-sensitive K (K(ATP)) channel blocker, prevents ischemic preconditioning. This study aimed to investigate the effects of chronic treatment with glibenclamide during two sequential exercise tests. METHODS: Forty patients with angina pectoris were divided into three groups: 20 nondiabetics (NDM), 10 patients with diabetes in treatment with glibenclamide (DMG) and 10 diabeticpatients with other treatments (DMO). All patients underwent two consecutive exercise tests. RESULTS: Heart rate and rate-pressure product at 1.0 mm ST-segment depression significantly increased during the second exercise test in NDM group (121.3+/-16.5 vs 127.3+/-15.3 beats/min, P<0.001, and 216.7+43.1 vs 232.1+/-43.0 beats.min-1.mmHg.10(2), P<0.001), and in DMO group (114.1+/-19.6 vs 119.6+/-18.1 beats/min, P=0.001, and 199.8+/-36.6 vs 222.2+/-29.2 beats.min-1.mmHg.10(2), P=0.019), but it did not change in patients in DMG group (130.7+/-14.5 vs 132.1+/-4.7 beats/min, P=ns, and 251.7+/-47.2 vs 250.3+/-42.8 beats.min-1.mmHg.10(2), P=ns). In the three groups, NDM, DMO, and DMG, the time to 1.0 mm ST-segment depression during the second exercise test was greater than during the first (225.0+/-112.5 vs 267.0+/-122.3 seconds, P=0.006; 187.5+/-54.0 vs 226.5+/-74.6 seconds, P=0.029 and 150.0+/-78.7 vs 186.0+/-81.9 seconds, P<0.001). CONCLUSION: The chronic use of glibenclamide may have mediated the loss of preconditioning benefits in the warm-up phenomenon, probably through its KATP channel-blocker activity, but without acting upon the tolerance to exercise.
Authors: Whady Hueb; Paulo R Soares; Bernard J Gersh; Luiz A M César; Protásio L Luz; Luiz B Puig; Eulógio M Martinez; Sergio A Oliveira; José A F Ramires Journal: J Am Coll Cardiol Date: 2004-05-19 Impact factor: 24.094
Authors: K M Detre; M S Lombardero; M M Brooks; R M Hardison; R Holubkov; G Sopko; R L Frye; B R Chaitman Journal: N Engl J Med Date: 2000-04-06 Impact factor: 91.245
Authors: Y Okazaki; K Kodama; H Sato; M Kitakaze; A Hirayama; M Mishima; M Hori; M Inoue Journal: J Am Coll Cardiol Date: 1993-06 Impact factor: 24.094
Authors: Charles E Leonard; Sean Hennessy; Xu Han; David S Siscovick; James H Flory; Rajat Deo Journal: Trends Endocrinol Metab Date: 2017-05-22 Impact factor: 12.015
Authors: Rosa Maria Rahmi; Augusto Hiroshi Uchida; Paulo Cury Rezende; Eduardo Gomes Lima; Cibele Larrosa Garzillo; Desiderio Favarato; Celia M C Strunz; Myrthes Takiuti; Priscyla Girardi; Whady Hueb; Roberto Kalil Filho; José A F Ramires Journal: Diabetes Care Date: 2012-12-18 Impact factor: 19.112
Authors: Leandro M A Costa; Paulo C Rezende; Rosa M R Garcia; Augusto H Uchida; Luis Fernando B C Seguro; Thiago L Scudeler; Edimar A Bocchi; Jose E Krieger; Whady Hueb; José Antonio F Ramires; Roberto Kalil Filho Journal: Medicine (Baltimore) Date: 2015-08 Impact factor: 1.817